mardi 27 septembre 2016

Onco Actu du 27 septembre 2016

2. Etiologie

Research finds talc doesn’t cause cancer; juries disagree [STAT]

Your bra could kill you – and other breast cancer myths busted [The Guardian]

3.2 Prévention - Obésité

How Our Health-Care System Is Feeding the Obesity Epidemic [Time]

4. Dépistage, diagnostic et pronostic

Pernicious PR Promotion of Overdiagnosis – my talk at Barcelona conference [HealthNewsReview]

4.12 Biopsies liquides

Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Research Report 2016 [ReportsnReports]

4.2 Dép., diag. & prono. - Génome

Myriad to Present New myRisk Hereditary Cancer Data Further Demonstrating the Benefits of Gene Panel Testing [Myriad]

5.12 Immunothérapies

Ratio of Certain Immune Cells to Tumor Burden Correlated With Outcome For Pembrolizumab-treated Patients With Melanoma [AACR]

Immunotherapy Patients Should Be Monitored for Destructive Thyroiditis [Cancer Network]

5.12.2 Immunothérapies - CAR-T

Kite Pharma Announces Positive Topline KTE-C19 Data from ZUMA-1 Pivotal Trial in Patients with Aggressive Non-Hodgkin Lymphoma (NHL) [Kite Pharma]

Kite Unveils Anticipated CAR-T Cancer Data: Positive But Not Complete [Xconomy]

Novel cancer treatment from Kite Pharma notches positive results, but big questions remain [STAT]

Kite Pharma Claims CAR-T Trial Victory, FDA Filing Next [The Street]

Kite’s groundbreaking CAR-T hits key study goal, heads to the FDA [EndPoints]

Kite immunotherapy drug helps blood cancer patients in study [Reuters]

5.12.3 Immunothérapies-combinaisons

Combining Cytokine-based Immunotherapy AM0010 with Pembrolizumab Yielded Durable Responses in Patients with Advanced Solid Tumors [AACR]

5.2 Pharma

Pfizer Says They Won’t Break Up [In the Pipeline]

Pfizer won’t split into two companies, so what’s next? [STAT]

5.2.1 Pharma - Partenariats

MD Anderson Cancer Center and Adaptimmune form strategic alliance to advance development of immunotherapies targeting multiple cancers [MD Anderson]

Adaptimmune, MD Anderson do I/O deal in T-cell receptors [FierceBiotech]

5.2.3 Pharma - économie

Array up by more than half on PhIII melanoma combo data [FierceBiotech]

5.3 Traitements - FDA, EMA,...

EU-US collaboration to boost medicine development for rare diseases [EMA]

5.3.4 Traitements - AMM (FDA, EMA)

AbbVie Announces Submission of a Supplemental New Drug Application for Ibrutinib (IMBRUVICA®) for Treatment of Marginal Zone Lymphoma [AbbVie]

5.9.1 ASTRO

Reduced radiation boost volume recommended but craniospinal axis dose remains unchanged for average-risk pediatric medulloblastoma [ASTRO]

Advances in radiation therapy have improved survival rates for early stage lung cancer patients [ASTRO]

Post-operative stereotactic radiosurgery a new standard of care for patients with resected brain metastases [ASTRO]

Hypofractionated radiation therapy can halve treatment time for poor performance status lung cancer patients [ASTRO]

SBRT offers prostate cancer patients high cancer control and low toxicity in fewer treatments [ASTRO]

Extremely hypofractionated radiation therapy shows promising toxicity results for intermediate risk prostate cancer patients [ASTRO]

Three novel intrinsic subtypes of prostate cancer identified [ASTRO]

6. Lutte contre les cancers

A cancer researcher races to find a cure — for his own incurable cancer [STAT]

6.1 Observation

Take a Number: Some Good News on Ovarian Cancer [NY Times]

6.6 Publications

Error in one line of code sinks cancer study [Retraction Watch]